Physician profile
Howard D Solomon
NPI 1467472761
$1,593.98
in general payments reported to CMS, 2019-2025
15 companies · $92.08 in 2025
The $92.08 reported for 2025 was less than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $460 · 2020: $154 · 2021: $311 · 2022: $257 · 2023: $234 · 2024: $86.31 · 2025: $92.08.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $412.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $412.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $348.78 | 2019-2023 | |
| Abbvie INC. | $321.69 | 2019-2025 | Skyrizi |
| Lilly USA, LLC | $258.24 | 2019-2023 | Olumiant |
| Regeneron Healthcare Solutions, INC. | $181.73 | 2019-2021 | |
| Janssen Biotech, INC. | $124.14 | 2022-2025 | Tremfya |
| Amgen INC. | $78.94 | 2021-2023 | Otezla |
| Arcutis Biotherapeutics, INC. | $64.06 | 2024 | Zoryve |
| Strata Skin Sciences, INC. | $52.50 | 2019-2024 | Xtrac |
| Sun Pharmaceutical Industries INC. | $40.85 | 2020-2021 | |
| Incyte Corporation | $25.36 | 2025 | Opzelura |
| Ucb, INC. | $22.34 | 2022 | |
| Leo Pharma INC. | $20.92 | 2021 | |
| Novartis Pharmaceuticals Corporation | $19.56 | 2023 | |
| Biofrontera INC. | $18.09 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $16.78 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Howard Solomon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.